These results support the findings presented above with NSCLC cell lines and suggest that decreased Chk1 and phospho-cdc2 (Tyr15) levels may be sensitive pharmacodynamic markers for HDACi efficacy in patient tumor samples to predict and assess patient response to HDACi treatment in clinical studies. The gene discussed is CHEK1; the disease is neoplasm.